Integrative genomics identifies the molecular basis of resistance to Azacytidine therapy in Myelodysplastic Syndromes

ABSTRACT: RNA-seq of bone marrow CD34+ cells of myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) patients to identify at the molecular pathways involved in primary resistance to AZA therapy.

ORGANISM(S): Homo sapiens

PROVIDER: GSE76203 | GEO | 2017/07/20

SECONDARY ACCESSION(S): PRJNA306622

REPOSITORIES: GEO